NPIF Equity

Inova acquires IN-PART, matchmaking platform for academia-industry collaboration

Inova announces the acquisition of IN-PART, a digital matchmaking platform dedicated to academia-industry collaboration. Along with the recent acquisition of Labiotech, this move consolidates Inova’s position as a leader and pioneer in the digitalization of the biopharma partnering space, supported by the €60 million investment from global investment firm Carlyle (NASDAQ: CG) and reaffirmation of a strong commitment by NextStage AM, in 2021.

Inova supports more than 160 global clients, including many of the world’s largest pharmaceutical companies, and is at the forefront of digital transformation in biopharma collaborations. Inova’s flagship product, Inova Partnering Platform, serves as a collaborative tool used to manage all potential partnerships related to outsourced innovation to pharma and biotechs, enabling customers to source leads, execute transactions, and manage alliances and virtual events.

IN-PART develops curated digital solutions that drive impact from research by streamlining relationships between industry professionals and the world of academic institutions. IN-PART’s matchmaking platform, Connect, is used by 250+ universities and research institutes to find new partners for commercialization across more than 6,000 companies. The company’s bespoke scouting platform, Discover, is used by sector leaders to engage academics, TTOs, and research service departments in more than 1,500 institutes with specific R&D challenges or requirements.

This acquisition is a major step forward for academia-industry partnering. While IN-PART will continue to service and expand its platforms for all research sectors, by joining forces with Inova, the company will gain access to Inova’s software infrastructure, as well as their market-leading teams in product and marketing. In turn, Inova clients will benefit from access to IN-PART search and discovery platforms, as well as leveraging best practice in matchmaking technology. By creating a stronger, more connected research ecosystem, this acquisition will ensure academic breakthroughs have an even greater impact on society.

“The Inova team is growing with talents and resources that are taking life science partnering to the next level. There is a growing consensus in the biopharma partnering world that academia is the next game-changer. However, our customers often report how difficult it is to navigate the extensive science produced by university groups. IN-PART has built an impressive digital solution to tackle this exact challenge and by acquiring them, we are now bringing our mission full-circle and including academia in the next gen partnering world. Together, we’re helping untapped science reach the market through smart partnering.” Gilles Toulemonde, Founder and CEO of Inova

“In Inova, we’ve found a great strategic fit across our technology base and close alignment in terms of company values and culture. It will give us access to a lot more resources and expertise for IN-PART to accelerate its growth and achieve its vision of connecting the academia-industry ecosystem, across all the research fields and sectors we work with. It’s a big moment for us and we’re looking forward to the next part of our journey with the amazing team at Inova.” Patrick Speedie, Co-founder and Director of IN-PART.

“The recent sale of IN-PART to Inova is great news for a management team of an innovative business from Sheffield that has been recognised on the global stage. We are really pleased that a business that we have supported from seed to scale up from both our EIS funds and NPIF has demonstrated the value to be found across the UK’s regions.” Sandy Reid, Deputy Fund Principal, Mercia Asset Management PLC

“It was clear from the start with Inova that there was synergy between our vision and approach. Inova provides clients with sector-leading Partnering software that fits perfectly with our matchmaking platform and search solution, Discover. The union of our companies, along with the exchange of expertise and technology across our teams will allow us to accelerate the pace at which we’re helping to surface the next generation of treatments and technologies.” Robin Knight, Co-founder and Director of IN-PART.